Research graph
References from Concomitant anti–tumor necrosis factor and anti–interleukin 17 therapy in severe, refractory hidradenitis suppurativa: A case series. Local targets link to admitted publications; unresolved targets remain external evidence.
Two phase 3 trials of adalimumab for hidradenitis suppurativa
10.1056/nejmoa1504370 · 2016 · External reference
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
10.1016/s0140-6736(23)00022-3 · 2023 · External reference
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
10.1016/s0140-6736(24)00101-6 · 2024 · External reference
Concurrent anticytokine biologics for the management of severe hidradenitis suppurativa: are they safe and effective?
2018 · External reference
Dual Blocking of IL17A and IL36R for the treatment of refractory hidradenitis suppurativa: a case report
2025 · External reference
